Advanced search
1 file | 1.84 MB Add to list

Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity

Author
Organization
Project
Abstract
Immunogenic cell death significantly contributes to the success of anti-cancer therapies, but immunogenicity of different cell death modalities widely varies. Ferroptosis, a form of cell death that is characterized by iron accumulation and lipid peroxidation, has not yet been fully evaluated from this perspective. Here we present an inducible model of ferroptosis, distinguishing three phases in the process-'initial' associated with lipid peroxidation, 'intermediate' correlated with ATP release and 'terminal' recognized by HMGB1 release and loss of plasma membrane integrity-that serves as tool to study immune cell responses to ferroptotic cancer cells. Co-culturing ferroptotic cancer cells with dendritic cells (DC), reveals that 'initial' ferroptotic cells decrease maturation of DC, are poorly engulfed, and dampen antigen cross-presentation. DC loaded with ferroptotic, in contrast to necroptotic, cancer cells fail to protect against tumor growth. Adding ferroptotic cancer cells to immunogenic apoptotic cells dramatically reduces their prophylactic vaccination potential. Our study thus shows that ferroptosis negatively impacts antigen presenting cells and hence the adaptive immune response, which might hinder therapeutic applications of ferroptosis induction. Inducing ferroptosis of tumour cells is a promising therapeutic approach in cancer. Authors show here that on the other hand, cells dying via ferroptosis are less immunogenic than necroptotic cells, they inhibit maturation and antigen cross-presentation of dendritic cells, hence lessen the anti-tumour immune response.
Keywords
T-CELLS, DEATH, PHOSPHATIDYLSERINE, PHAGOCYTOSIS, RECEPTOR, EXPOSURE, NECROSIS, STRESS

Downloads

  • 4790 22Wiernicki.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • application/octet-stream
    • |
    • 1.84 MB

Citation

Please use this url to cite or link to this publication:

MLA
Wiernicki, Bartosz, et al. “Cancer Cells Dying from Ferroptosis Impede Dendritic Cell-Mediated Anti-Tumor Immunity.” NATURE COMMUNICATIONS, vol. 13, no. 1, 2022, doi:10.1038/s41467-022-31218-2.
APA
Wiernicki, B., Maschalidi, S., Pinney, J., Adjemian Catani, S., Vanden Berghe, T., Ravichandran, K., & Vandenabeele, P. (2022). Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. NATURE COMMUNICATIONS, 13(1). https://doi.org/10.1038/s41467-022-31218-2
Chicago author-date
Wiernicki, Bartosz, Sophia Maschalidi, Jonathan Pinney, Sandy Adjemian Catani, Tom Vanden Berghe, Kodi Ravichandran, and Peter Vandenabeele. 2022. “Cancer Cells Dying from Ferroptosis Impede Dendritic Cell-Mediated Anti-Tumor Immunity.” NATURE COMMUNICATIONS 13 (1). https://doi.org/10.1038/s41467-022-31218-2.
Chicago author-date (all authors)
Wiernicki, Bartosz, Sophia Maschalidi, Jonathan Pinney, Sandy Adjemian Catani, Tom Vanden Berghe, Kodi Ravichandran, and Peter Vandenabeele. 2022. “Cancer Cells Dying from Ferroptosis Impede Dendritic Cell-Mediated Anti-Tumor Immunity.” NATURE COMMUNICATIONS 13 (1). doi:10.1038/s41467-022-31218-2.
Vancouver
1.
Wiernicki B, Maschalidi S, Pinney J, Adjemian Catani S, Vanden Berghe T, Ravichandran K, et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. NATURE COMMUNICATIONS. 2022;13(1).
IEEE
[1]
B. Wiernicki et al., “Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity,” NATURE COMMUNICATIONS, vol. 13, no. 1, 2022.
@article{8762906,
  abstract     = {{Immunogenic cell death significantly contributes to the success of anti-cancer therapies, but immunogenicity of different cell death modalities widely varies. Ferroptosis, a form of cell death that is characterized by iron accumulation and lipid peroxidation, has not yet been fully evaluated from this perspective. Here we present an inducible model of ferroptosis, distinguishing three phases in the process-'initial' associated with lipid peroxidation, 'intermediate' correlated with ATP release and 'terminal' recognized by HMGB1 release and loss of plasma membrane integrity-that serves as tool to study immune cell responses to ferroptotic cancer cells. Co-culturing ferroptotic cancer cells with dendritic cells (DC), reveals that 'initial' ferroptotic cells decrease maturation of DC, are poorly engulfed, and dampen antigen cross-presentation. DC loaded with ferroptotic, in contrast to necroptotic, cancer cells fail to protect against tumor growth. Adding ferroptotic cancer cells to immunogenic apoptotic cells dramatically reduces their prophylactic vaccination potential. Our study thus shows that ferroptosis negatively impacts antigen presenting cells and hence the adaptive immune response, which might hinder therapeutic applications of ferroptosis induction. Inducing ferroptosis of tumour cells is a promising therapeutic approach in cancer. Authors show here that on the other hand, cells dying via ferroptosis are less immunogenic than necroptotic cells, they inhibit maturation and antigen cross-presentation of dendritic cells, hence lessen the anti-tumour immune response.}},
  articleno    = {{3676}},
  author       = {{Wiernicki, Bartosz and Maschalidi, Sophia and Pinney, Jonathan and Adjemian Catani, Sandy and Vanden Berghe, Tom and Ravichandran, Kodi and Vandenabeele, Peter}},
  issn         = {{2041-1723}},
  journal      = {{NATURE COMMUNICATIONS}},
  keywords     = {{T-CELLS,DEATH,PHOSPHATIDYLSERINE,PHAGOCYTOSIS,RECEPTOR,EXPOSURE,NECROSIS,STRESS}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{15}},
  title        = {{Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity}},
  url          = {{http://doi.org/10.1038/s41467-022-31218-2}},
  volume       = {{13}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: